Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Valeant to restate earnings
View:
Post by cashflow98 on Feb 22, 2016 5:29pm

Valeant to restate earnings

Valeant to restate earnings after internal review-CNBC, citing DJ less than 1 minute ago by Thomson Reuters Feb 22 (Reuters) - Valeant Pharmaceuticals International Inc is expected to restate its earnings after an internal review that likely concerns sales of its drugs to specialty pharmacy Philidor Rx Services, CNBC reported, citing Dow Jones. Valeant cut ties with Philidor in October after it was revealed Philidor used aggressive tactics to try to increase insurer reimbursement, mostly for dermatology drugs to help the Canadian drugmaker inflate revenue. (https://bit.ly/1mTDt79) (Reporting by Ramkumar Iyer in Bengaluru; Editing by Maju Samuel)
Comment by FootballFan1 on Feb 22, 2016 5:41pm
Here's a report by CBC: Valeant shares sink anew on report it may restate earnings CBC News Posted: Feb 22, 2016 4:24 PM ET| Last Updated: Feb 22, 2016 5:20 PM ET Shares of Valeant Pharmaceuticals plunged anew after-hours on Monday after the Wall Street Journal reported that the drugmaker may restate earnings after an internal review. "Valeant ... likely needs to restate some of its ...more  
VALEANT PHARMACEUTICALS INTL INC
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities